ADAR1 Capital Buys Rallybio Shares, Signaling Confidence in Rare‑Disease Pipeline
ADAR1 Capital’s new stake in Rallybio signals confidence after a stalled merger, offering insight into biotech investor sentiment and future clinical milestones.
4 minutes to read